Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.
- Presentation
Diagnosis and Stepwise Treatment of Frontal Fibrosing Alopecia
Description
The speaker reviews how they evaluate and treat frontal fibrosing alopecia (FFA), emphasizing that it is a common scarring alopecia seen mostly in older women with gradual hairline recession, loss of sideburns, and frequent eyebrow involvement. Diagnosis relies on careful history, baseline photography, and measurements from the outer canthus, glabella, and sideburns, along with trichoscopy findings such as loss of follicular openings, perifollicular hyperkeratosis, erythema, and inflammation. Because FFA is a trichologic emergency and hair loss is usually irreversible, early treatment is important and patients should be counseled that stabilization may take months. The treatment approach is stepwise: rapidly progressive cases may receive a short prednisone taper; slower cases may be managed with topical tacrolimus, clobetasol, and minoxidil combined with intralesional triamcinolone. More extensive disease may require dutasteride or finasteride, hydroxychloroquine with weight-based dosing, low-dose doxycycline, oral minoxidil, pioglitazone, naltrexone, mycophenolate, methotrexate, cyclosporine, retinoids, excimer laser, or JAK inhibitors such as upadacitinib, ruxolitinib, or delgocitinib. He also discusses facial papules/cobblestoning, the role and risks of corticosteroid injections, rare ocular complications, and avoidance of hair transplants, brow lifts, deep peels, chemical sunscreens, and fragrances. Mineral sunscreen is preferred, and the overall goal is to stop progression rather than regrow lost hair.
View moreConclusions
- Frontal fibrosing alopecia is best treated as an early, progressive scarring hair-loss emergency because lost hair usually does not regrow.
- The main goal of therapy is to stabilize disease and halt inflammation, not to reliably restore hair density.
- Most patients in the speaker’s experience are women and eyebrow involvement is very common, so eyebrow examination is essential in evaluation.
- A stepwise regimen using topical tacrolimus, clobetasol, minoxidil, and intralesional triamcinolone can stabilize many patients, though response may take many months.
- More extensive or rapidly progressive disease often requires escalation to 5-alpha reductase inhibitors, hydroxychloroquine, doxycycline, and other systemic agents.
- Low-dose doxycycline appears to work about as well as high-dose doxycycline for inflammatory control while causing fewer side effects.
- Dutasteride emerges as one of the most effective systemic options, especially in postmenopausal patients.
- Corticosteroids can reduce inflammation, but chronic use may have follicular and tissue-related downsides, so steroid-sparing strategies are important.
- Intralesional steroid injections can help but require caution because of local atrophy risk and rare ocular complications such as central serous chorioretinopathy.
- JAK inhibitors, especially topical ruxolitinib and delgocitinib, show promise for reducing inflammatory activity and improving symptoms and facial papules.
- Facial papules and cobblestoning are important associated features of FFA and may be a major cosmetic concern for patients.
- Certain cosmetic and environmental products, especially fragranced sunscreens and moisturizers, may be associated with FFA or worsen symptoms, so mineral-based, fragrance-free products are preferred.
- Procedures such as hair transplantation, brow lifts, and deep facial peels may worsen FFA and should generally be avoided.
- Overall management works best when individualized, monitored with serial measurements and photos, and combined with patient counseling about realistic expectations and long treatment timelines.
- Guidelines for clinical trials of frontal fibrosing alopecia: consensus recommendations from the International FFA Cooperative Group (IFFACG)#10.1002/9781119829072.ch30
- Frontal fibrosing alopecia: a retrospective clinical review of 62 patients with treatment outcome and long-term follow-up#10.1111/ijd.12479
- Prognosis, treatment, and disease outcomes in frontal fibrosing alopecia: A retrospective review of 92 cases#10.1016/j.jaad.2017.07.035
- The Double-Edged Effect of Chronic Corticosteroid Use in Scarring Alopecia: A Call for Further Investigation#10.1111/ijd.70361
- Central serous chorioretinopathy after scalp and eyebrow intralesional triamcinolone acetonide injections: Report of two cases#10.1016/j.jdcr.2024.06.034
- The use of topical ruxolitinib 1.5% cream in frontal fibrosing alopecia: A case report#10.1016/j.jdcr.2024.04.034
- Randomized Controlled Trial of the Topical Jak Inhibitor Delgocitinib Cream in Patients with Frontal Fibrosing Alopecia#10.1016/j.jid.2025.09.375
- Figure 2. Changes in frontal fibrosing alopecia severity score and Lichen Planopilaris Activity Index in patients with frontal fibrosing alopecia treated with delgocitinib cream or cream vehicle#10.5772/intechopen.106230
- Figure 1. Changes in the transcriptome of lesions in patients with frontal fibrosing alopecia treated with delgocitinib cream or cream vehicle
- Efficacy and tolerability of low-dose versus high-dose doxycycline in the management of lymphocytic scarring alopecias#10.1016/j.jaad.2025.02.028
- Effectiveness of dutasteride in a large series of patients with frontal fibrosing alopecia in real clinical practice#10.1016/j.jaad.2021.02.089